GILEAD SCIENCES, INC. Payments to Acquire Marketable Securities
GILEAD SCIENCES, INC. (GILD) reported Payments to Acquire Marketable Securities of $1.77 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2023-02-22
- GILEAD SCIENCES, INC. payments to acquire marketable securities for fiscal 2022 was $1.77B, a 49.67% decline from fiscal 2021.
- GILEAD SCIENCES, INC. payments to acquire marketable securities for fiscal 2021 was $3.52B, a 82.69% decline from fiscal 2020.
- GILEAD SCIENCES, INC. payments to acquire marketable securities for fiscal 2020 was $20.32B, a 33.30% decline from fiscal 2019.
- GILEAD SCIENCES, INC. payments to acquire marketable securities for fiscal 2019 was $30.45B, a 197.62% increase from fiscal 2018.
| Period end | Payments to Acquire Marketable Securities 12 month |
|---|---|
| 2022-12-31 | $1.77B 10-K · filed 2023-02-22 |
| 2021-12-31 | $3.52B 10-K · filed 2023-02-22 |
| 2020-12-31 | $20.32B 10-K · filed 2023-02-22 |
| 2019-12-31 | $30.45B 10-K · filed 2022-02-23 |
| 2018-12-31 | $10.23B 10-K · filed 2021-02-25 |
| 2017-12-31 | $23.31B 10-K · filed 2020-02-25 |
| 2016-12-31 | $25.62B 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |